GGrantIndex
← Search

Leadership, Planning and Evaluation

$307,092P30FY2024CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications, trials & patents

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

Abstract Leadership, Planning, and Evaluation The senior leadership of the City of Hope Comprehensive Cancer Center (COHCCC) is composed of highly qualified members who bring their respective strengths and unique backgrounds to drive the progress of the center. It is led by Steven T. Rosen, MD, Director, Larry Kwak, MD, PhD, Deputy Director, and nine Associate Directors in the domains of Basic Sciences, Clinical Sciences, Population Sciences, Health Equity, Community Outreach and Engagement, Informatics and Computational Biology, Education and Training, Shared Resources, and Administration. With their distinct qualifications, members have worked individually or in collaboration to expand the center, reach new milestones, and further benefit our community. COHCCC leadership has a wide array of advisory input to assist in planning for the Center's next steps and evaluating the outcomes of Center programs and policy implementation. Internal advisors include Program and Shared Resource leaders, oversight committees, and the chairs of clinical and research departments, all of whom contribute to shaping our future direction through internal evaluation processes. Our External Advisory Board continues to play a significant role in reviewing our strategic plans and advising on our course of action. We have responded to their recommendations and by virtue of their guidance have 1) integrated the faculty and the shared / genomic resources of TGen within the COHCCC membership, 2) restructured and enhanced our Mass Spectrometry Shared Resource, 3) established the Department of Diabetes and Cancer Metabolism, and 4) initiated the Integrated Drug Development Venture to accelerate translation of scientific discoveries to first-in-human trials. External relationships are also fostered by Community Outreach & Engagement, which has established partnerships between the scientific community and organizations that support minority engagement. Strategic planning is critical to the development of future programs that advance COHCCC priorities, detailing how we will execute our unwavering commitment to drive paradigm shifts to more effectively prevent, diagnose, and treat cancer. Because of the innovative structure of our institution as a stand-alone cancer center, we are uniquely positioned to realize breakthrough advances in basic science, clinical trials, and patient care. COHCCC engages in a 5-year strategic planning process involving many collaborating partners, including COHCCC faculty, staff, patients, and stakeholders, each providing crucial input and valuable feedback. The approach includes data collection and analysis, multiple interviews with key parties, and an iterative review and approval process of the final deliverable. A new plan was launched in October 2021 with an emphasis on 1) Precision Medicine, 2) Cellular Therapeutics, 3) Health Equity, and 4) Clinical Networks. Performance and progress of the stated goals within the plan are tracked and catalogued on an ongoing basis.

View original record on NIH RePORTER →